C. Porter

发表

Enhancement of microbubble mediated gene delivery by simultaneous exposure to ultrasonic and magnetic fields

E. Stride, C. Porter, A. G. Prieto, 2008 .

Cationic Liposomes Enhance the Rate of Transduction by a Recombinant Retroviral Vector In Vitro and In Vivo

C. Porter, G. Box, K. Lukacs, 1998, Journal of Virology.

Molluscum contagiosum virus.

C. Porter, N. Blake, L. Archard, 1992, Molecular and cell biology of human diseases series.

Sensitization of cells and retroviruses to human serum by (αl-3) galactosyltransferase

C. Porter, F. Cosset, R. Weiss, 1996, Nature.

Sensitization of cells and retroviruses to human serum by (alpha 1-3) galactosyltransferase.

C. Porter, F. Cosset, R. Weiss, 1996, Nature.

Sensitization of rhabdo-, lenti-, and spumaviruses to human serum by galactosyl(alpha1-3)galactosylation

C. Porter, P. Bieniasz, R. Weiss, 1997, Journal of virology.

Spatial and acoustic pressure dependence of microbubble‐mediated gene delivery targeted using focused ultrasound

C. Porter, J. Bamber, N. Bush, 2006, The journal of gene medicine.

Comparison of efficiency of infection of human gene therapy target cells via four different retroviral receptors.

C. Porter, F. Cosset, R. Weiss, 1996, Human gene therapy.

Primary attachment of murine leukaemia virus vector mediated by particle-associated heparan sulfate proteoglycan.

C. Porter, Nina Kureishy, Daisy Faruque, 2006, The Biochemical journal.

Spatial Control of Microbubble-Mediated Non-Viral Gene Delivery Using Focused Ultrasound

C. Porter, J. Bamber, N. Bush, 2007 .

Generation of a high titre retroviral vector for endothelial cell-specific gene expression in vivo

C. Porter, G. Mavria, U. Jäger, 2000, Gene Therapy.

Endothelial Cell-Specific Transcriptional Targeting from a Hybrid Long Terminal Repeat Retrovirus Vector Containing Human Prepro-Endothelin-1 Promoter Sequences

C. Porter, U. Jäger, Yuan Zhao, 1999, Journal of Virology.

Efficient retroviral transduction of human bone marrow progenitor and long-term culture-initiating cells: partial reconstitution of cells from patients with X-linked chronic granulomatous disease by gp91-phox expression.

C. Porter, R. Levinsky, C. Kinnon, 1996, Blood.

p22-phox-deficient chronic granulomatous disease: reconstitution by retrovirus-mediated expression and identification of a biosynthetic intermediate of gp91-phox.

C. Porter, R. Levinsky, A. Verhoeven, 1994, Blood.

Anti-&agr;Gal-dependent complement-mediated cytotoxicity in metastatic melanoma

C. Porter, J. Larkin, M. Gore, 2006, Melanoma research.

Microvascular free tissue transfer for gene delivery: in vivo evaluation of different routes of plasmid and adenoviral delivery

C. Porter, A. Melcher, H. Pandha, 2009, Gene Therapy.

Retroviral vectors for suicide gene therapy.

C. Porter, 2004, Methods in molecular medicine.

X-linked chronic granulomatous disease: correction of NADPH oxidase defect by retrovirus-mediated expression of gp91-phox.

C. Porter, R. Levinsky, C. Kinnon, 1993, Blood.

Complement insufficiency limits efficacy in a xenograft model of hyperacute rejection for cancer therapy

C. Porter, J. Larkin, 2006, Cancer Immunology, Immunotherapy.

Mice are unsuitable for modelling ABO discordance despite strain‐specific A cross‐reactive natural IgM

C. Porter, James M.G. Larkin, 2005, British journal of haematology.

Superoxide production by normal and chronic granulomatous disease (CGD) patient-derived EBV-transformed B cell lines measured by chemiluminescence-based assays.

C. Porter, R. Levinsky, C. Kinnon, 1992, Journal of immunological methods.

The Adhesion Molecules, PECAM-1, ICAM-3 and CD33, on CD34+ Haematopoietic Progenitor Cells

C. Porter, J. Hatzfeld, A. Hatzfeld, 1996 .

Sensitization of human cells to lysis by human complement as an approach for cancer gene therapy.

C. Porter, Y. Takeuchi, U. Jäger, 1998, Advances in experimental medicine and biology.

Rescue of retroviral envelope fusion deficiencies by cationic liposomes

C. Porter, 2002, The journal of gene medicine.

Characterization and physical mapping of Molluscum contagiosum virus DNA and location of a sequence capable of encoding a conserved domain of epidermal growth factor.

C. Porter, L. Archard, 1987, The Journal of general virology.

Gene Technology

C. Porter, J. Hatzfeld, A. Hatzfeld, 1996, NATO ASI Series.

Detection of gp91-phox precursor protein in B-cell lines from patients with X-linked chronic granulomatous disease as an indicator for mutations impairing cytochrome b558 biosynthesis.

C. Porter, C. Kinnon, D. Roos, 1996, The Biochemical journal.

Inactivation of murine leukaemia virus by exposure to visible light.

C. Porter, T. Richardson, 2005, Virology.

In vivo efficacy of HSV‐TK transcriptionally targeted to the tumour vasculature is augmented by combination with cytotoxic chemotherapy

C. Porter, K. Harrington, C. Marshall, 2005, The journal of gene medicine.

Characterization of a molluscum contagiosum virus homolog of the vaccinia virus p37K major envelope antigen

C. Porter, N. Blake, L. Archard, 1991, Journal of virology.

Targeted retroviral gene delivery using ultrasound

C. Porter, J. Bamber, N. Bush, 2007, The journal of gene medicine.

Physical parameters affecting ultrasound/microbubble-mediated gene delivery efficiency in vitro.

Jeffrey C Bamber, Gail R ter Haar, C. Porter, 2006, Ultrasound in medicine & biology.

Enhancement of microbubble mediated gene delivery by simultaneous exposure to ultrasonic and magnetic fields.

Colin Porter, Eleanor Stride, C. Porter, 2009, Ultrasound in medicine & biology.

Atrial corrected Fourier amplitude ratios for the scintigraphic quantitation of valvar regurgitation

C. Porter, E. Botvinick, M. Dae, 1984 .

Molluscum contagiosum virus types in genital and non‐genital lesions

C. Porter, N. Blake, L. Archard, 1989, The British journal of dermatology.

Molluscum contagiosum: characterization of viral DNA and clinical features

C. Porter, L. Archard, J. Cream, 1987, Epidemiology and Infection.

Detection of gp 91-phox precursor protein in B-cell lines from patients with X-linked chronic granulomatous disease as an indicator for mutations impairing cytochrome b 558 biosynthesis

C. Porter, C. Kinnon, D. Roos, 1996 .